Strides Pharma Science Ltd
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
- Market Cap ₹ 7,304 Cr.
- Current Price ₹ 792
- High / Low ₹ 828 / 322
- Stock P/E 123
- Book Value ₹ 346
- Dividend Yield 0.32 %
- ROCE 4.66 %
- ROE 1.75 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 109%
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.81% over past five years.
- Promoter holding is low: 28.3%
- Company has a low return on equity of 1.46% over last 3 years.
- Promoters have pledged 52.0% of their holding.
- Earnings include an other income of Rs.2,873 Cr.
- Company has high debtors of 248 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,064 | 929 | 2,162 | 1,382 | 1,470 | 1,537 | 1,692 | 1,858 | 1,979 | 1,854 | 2,153 | 2,139 | |
914 | 795 | 1,894 | 1,255 | 1,271 | 1,402 | 1,487 | 1,698 | 1,902 | 1,755 | 1,898 | 1,877 | |
Operating Profit | 150 | 134 | 268 | 127 | 199 | 135 | 205 | 159 | 77 | 100 | 256 | 262 |
OPM % | 14% | 14% | 12% | 9% | 14% | 9% | 12% | 9% | 4% | 5% | 12% | 12% |
4,614 | 619 | 82 | 154 | 860 | 111 | 93 | 117 | 123 | 68 | 67 | 2,873 | |
Interest | 105 | 34 | 103 | 72 | 82 | 54 | 67 | 65 | 74 | 139 | 168 | 146 |
Depreciation | 47 | 49 | 103 | 70 | 78 | 83 | 94 | 99 | 104 | 94 | 85 | 85 |
Profit before tax | 4,612 | 669 | 145 | 139 | 899 | 109 | 136 | 112 | 22 | -65 | 70 | 2,905 |
Tax % | 24% | 20% | 10% | 22% | 1% | -1% | 12% | 30% | -738% | -107% | 6% | 1% |
3,513 | 532 | 130 | 109 | 892 | 110 | 120 | 78 | 180 | 5 | 65 | 2,886 | |
EPS in Rs | 589.42 | 89.32 | 14.58 | 12.14 | 99.62 | 12.33 | 13.42 | 8.72 | 20.07 | 0.52 | 7.13 | 313.04 |
Dividend Payout % | 86% | 121% | 34% | 37% | 2% | 24% | 104% | 29% | 0% | 289% | 35% | 1% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 5% |
3 Years: | 3% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | -7% |
5 Years: | -13% |
3 Years: | -30% |
TTM: | -16% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 32% |
3 Years: | 73% |
1 Year: | 97% |
Return on Equity | |
---|---|
10 Years: | 5% |
5 Years: | 2% |
3 Years: | 1% |
Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 60 | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 |
Reserves | 1,571 | 1,415 | 3,068 | 3,143 | 3,073 | 3,167 | 3,069 | 3,158 | 3,317 | 3,365 | 3,469 | 3,101 |
473 | 405 | 1,545 | 1,608 | 606 | 811 | 902 | 917 | 1,284 | 1,414 | 1,650 | 1,202 | |
337 | 273 | 602 | 641 | 517 | 595 | 616 | 1,056 | 743 | 750 | 627 | 636 | |
Total Liabilities | 2,440 | 2,152 | 5,304 | 5,481 | 4,285 | 4,663 | 4,677 | 5,221 | 5,434 | 5,620 | 5,838 | 5,031 |
381 | 394 | 984 | 1,194 | 564 | 574 | 651 | 644 | 617 | 597 | 556 | 807 | |
CWIP | 37 | 39 | 180 | 158 | 144 | 122 | 112 | 111 | 56 | 55 | 94 | 66 |
Investments | 1,047 | 968 | 2,447 | 2,520 | 1,777 | 2,149 | 2,171 | 2,395 | 2,400 | 2,492 | 2,498 | 1,848 |
976 | 750 | 1,693 | 1,609 | 1,801 | 1,818 | 1,743 | 2,072 | 2,361 | 2,476 | 2,689 | 2,311 | |
Total Assets | 2,440 | 2,152 | 5,304 | 5,481 | 4,285 | 4,663 | 4,677 | 5,221 | 5,434 | 5,620 | 5,838 | 5,031 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-3 | 207 | 83 | 412 | 66 | 40 | 138 | 283 | -283 | 242 | -36 | 421 | |
3,999 | 305 | -1,062 | -883 | 433 | -166 | 63 | -276 | 19 | -183 | -61 | -138 | |
-3,498 | -802 | 1,571 | -67 | -707 | 123 | -204 | -49 | 251 | 11 | 108 | -370 | |
Net Cash Flow | 497 | -290 | 592 | -538 | -208 | -3 | -3 | -42 | -13 | 70 | 11 | -86 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 94 | 101 | 117 | 143 | 112 | 138 | 141 | 161 | 239 | 257 | 256 | 248 |
Inventory Days | 80 | 110 | 113 | 204 | 126 | 197 | 189 | 254 | 170 | 168 | 155 | 145 |
Days Payable | 127 | 133 | 148 | 234 | 183 | 212 | 200 | 271 | 213 | 220 | 166 | 163 |
Cash Conversion Cycle | 47 | 77 | 82 | 112 | 55 | 123 | 130 | 144 | 196 | 205 | 244 | 230 |
Working Capital Days | 100 | 97 | 120 | 110 | 150 | 178 | 150 | 162 | 231 | 261 | 292 | 261 |
ROCE % | 11% | 9% | 6% | 5% | 24% | 4% | 5% | 4% | 2% | 2% | 5% | 5% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Senior VP Treasury Mr. Ramesh RJ retires after 30+ years with Strides Pharma on May 31, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
27 May - Strides reports FY25 revenue growth 17.2%, EBITDA INR803cr, PAT 12x higher, U.S. revenue $291M, strong outlook.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report confirms full regulatory compliance for FY ended March 31, 2025.
-
Intimation Pursuant To Regulation 31A Of The Sebl (LODR) Regulations, 2015 Regarding Promoter Reclassification
26 May - Strides applied for promoter reclassification of two entities to public category on May 26, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23 May - Newspaper Advertisement- Audited Financial Results for the Quarter and Financial Year ended March 31, 2025
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT REC
-
Oct 2024TranscriptPPT
-
Oct 2024Transcript PPT
-
Aug 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptPPT
-
Aug 2023TranscriptPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Dec 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Oct 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Business Segments
1) Pharma Generics: Its generic pharma business is driven by IP-based product licensing and global marketing and distribution partnerships. It specializes in manufacturing niche generic formulations in various dosage forms, like tablets, capsules, liquids, and sachets, focusing on regulated markets including the United States, Europe, Australia, etc. It has emerged as one of the world’s leading producers of soft gelatin capsules. [1] [2]